Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
editorial
. 2020 Apr 22;28(7):772–775. doi: 10.1016/j.jagp.2020.04.013

Electroconvulsive Therapy During COVID-19-Times: Our Patients Cannot Wait

Pascal Sienaert 1,, Simon Lambrichts 1, Leen Popleu 2,3, Elke Van Gerven 1,4, Satya Buggenhout 1,5, Filip Bouckaert 5
PMCID: PMC7195425  PMID: 32345550

Now is a crucial time for us to stand up

for our patients’ right to continued access to ECT

Randall T. Espinoza, Charles H. Kellner, & William V. McCall, 2020

The rapidly evolving pandemic of coronavirus disease 2019 (COVID-19) is a major challenge for health services and drastic measures have been taken to contain this global crisis. Anticipating a shortage of health-care providers, in particular anesthesiologists, hospitals around the world did not hesitate to close down their electroconvulsive therapy (ECT)-units. In Flanders, a region in Belgium with 6,596,000 inhabitants, 70% of the ECT-units stopped treatments from the start of the pandemic. The remaining have put treatments for older patients residing in nursing homes on hold. Reasons cited are unavailability of anesthesiologists rescheduled to work in intensive care units, shortage of muscle relaxants needed for mechanical ventilation of COVID-patients, and fear of virus transmission through bag-mask-ventilation during the ECT-procedure. Another reason for closing down the ECT-service is that ECT is considered an elective intervention, and that, moreover, ”psychiatry can wait.” It is not unusual for patients with a psychiatric disorder to experience poor access to health care compared with people without a psychiatric disorder.1 But, as eloquently argued by Espinoza et al.,2 in this COVID-era, "ECT is a lifesaving gem,” an often essential medical procedure that should not be discarded as an elective intervention.

OUR PATIENTS CANNOT WAIT

In this challenging time, the need to deliver care for older adults experiencing serious mental illness is higher than ever. ECT not only yields high remission rates in older patients,3 it is often life-saving in patients refusing food and fluid intake, or those with psychotic depression, catatonia, and suicidality.4 In considering the implications of COVID-19 for ECT, it is important for psychiatrists to carefully review the treatment needs in consultation with patients and their families. If ECT is stopped, the 6-month relapse rate with continuation pharmacotherapy will mount up to 37%.5 Relapse rates after discontinuing an ongoing maintenance-ECT (M-ECT) are similar.6 , 7 Moreover, it is of note that, apart from the burden caused by a depressive relapse, in this particular pandemic context, a depressive relapse might make older patients more vulnerable to infectious diseases. It is known that depression is associated with immunological impairments, especially in older adults,8 and that in stressful situations, mortality from viral respiratory infections is higher.9 Therefore, when M-ECT is withheld, or the intertreatment interval is lengthened, a close follow-up is of utmost importance. A protocol of using rescue ECT-sessions based on monitoring of psychiatric symptoms through televisits,10 using validated rating scales, and providing ECT only in case of early signs of relapse,11 should be considered standard clinical care in these exceptional times. This practice was shown to be feasible in a large trial on flexible M-ECT in older patients.12

In an attempt to contain the epidemic, the Belgian government issued on April 3th 2020 all day hospitalizations for persons over 65 years of age to be closed temporarily. As a consequence, M-ECT for outpatients was kept to a strict minimum. More specifically, older patients residing in nursing homes could not be treated on an outpatient basis, in order to protect their fellow-patients from infection. On a weekly basis, assessments were performed via telephone consultations with patients and/or care-providers. If possible, a standardized rating scale was used. Furthermore, cases were discussed on a weekly (video) ECT-team meeting. If signs of relapse were emerging, or in case of increasing suicidality, patients were readmitted to apply rescue ECT starting with ECT twice a week. Readmission was organized in a 7-day quarantine-regime, with close follow-up of clinical signs and screening for COVID through polymerase chain reaction (PCR) testing.

PROTECTING PATIENTS AND STAFF

To safely administer ECT, protecting staff and patients from exposure to respiratory droplets, our unit, situated in a tertiary psychiatric hospital, adopted a number of additional safety measures.

A nasopharyngeal swab for PCR-testing was performed the day before ECT. Hospitalized patients were monitored daily for symptoms of fever, coughing and dyspnea; PCR-testing was repeated once a week. Outpatients had PCR-testing the day before a treatment-session. Patients with a positive PCR-test were treated at the end of the program to prevent contamination of the treatment room and to enable rigorous cleaning afterwards.

The treatment room was adequately ventilated ensuring ventilation with air flow of 5 air changes per hour,13 and all medical devices and high touch surfaces were disinfected with a chlorine solution after every treatment. After treating a patient with a positive PCR-test the entire treatment room, including the floor, was cleaned with a chlorine solution.

The number of persons present in the treatment room was kept to the absolute minimum required for the patient's care (ECT-nurse, ECT-psychiatrist, anesthesiologist and assistant-anesthesiologist). Appropriate personal protective equipment was used, including a standard "filtering face piece” 2-respirator, eye protection, a fluid-resistant long-sleeved gown and gloves, as prescribed by the World Health Organization13 (Fig. 1 ). Filtering face piece 2-respirators were worn for a whole treatment day. Gloves were changed according to the 5 WHO indications for hand hygiene. Gowns were changed every treatment day, after a treatment of a COVID-positive patient, or in case of accidental contamination.

FIGURE 1.

FIGURE 1:

ECT-team wearing personal protective equipment, including FFP2-respirator, eye protection shield, fluid-resistant long-sleeved gown and gloves.

Glycopyrrolate was used routinely14 to prevent salivation, thus reducing the risk of producing aerosol. It is suggested that glycopyrrolate also prevents cerebral deoxygenation during ECT.15 A minor drawback of its use is the fact that patients may experience dry mouth upon recovery.

ECT-anesthesia typically involves manual ventilation through a tight mask connected with an open Bain circuit. Manual ventilation is an aerosol-generating procedure, shown to pose an increased risk of coronavirus transmission to healthcare workers.16 Oxygen-therapy, however, does not increase droplet count.17 On the other hand, it is suggested that hyperventilation, using a bag-mask, might increase seizure length and improve seizure adequacy.18 Nevertheless, in our unit, bag-mask-ventilation was avoided and patients were pre-oxygenated using a simple oxygen-mask (5 L/min).

Re-organizing ECT-care necessitates a re-allocation of resources. Trained practitioners are needed to perform telephone or video-assessments. Weekly supervision is necessary to assess the need of readmission and rescue ECT. Practitioners and policy makers of nearby regional ECT-units should combine forces to centralize ECT-care and continue treatments in a limited number of centers. Although this approach may cause inconvenience for some patients, it will increase expertise and limit the amount of personnel and resources needed to enable continued access to ECT.

In these exceptional times, in which we must all arm ourselves against the coronavirus-pandemic, treating the most vulnerable of our patients is of major importance. Within the limits imposed on us during this pandemic, ECT should be seen as an essential medical procedure and made available in order to prevent long-term mental health consequences in older adults already experiencing serious mental illness. The caveats and measures described here, can guide ECT-practitioners in the context of this viral pandemic.

Author Contribution

Pascal Sienaert: Conceptualization, Investigation, Writing —review & editing. Simon Lambrichts: Writing—review & editing. Leen Popleu: Review & editing. Satya Buggenhout: Review & editing. Elke Van Gerven: Review & editing. Filip Bouckaert: Writing— review & editing.

Disclosure

The authors have no disclosures to report.

References

  • 1.Henderson C, Noblett J, Parke H. Mental health-related stigma in health care and mental health-care settings. Lancet Psychiatry. 2014;1:467–482. doi: 10.1016/S2215-0366(14)00023-6. [DOI] [PubMed] [Google Scholar]
  • 2.Espinoza RT, Kellner CH, McCall WV. ECT: an essential medical procedure. J ECT. 2020 doi: 10.1097/YCT.0000000000000689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Meyer JP, Swetter SK, Kellner CH. Electroconvulsive therapy in geriatric psychiatry. Clin Geriatr Med. 2020;36:265–279. doi: 10.1016/j.cger.2019.11.007. [DOI] [PubMed] [Google Scholar]
  • 4.Kellner C, Obbels J, Sienaert P. When to consider electroconvulsive therapy (ECT): an expert review with clinical recommendations. Acta Psychiatrica Scand. 2020;141:304–315. doi: 10.1111/acps.13134. [DOI] [PubMed] [Google Scholar]
  • 5.Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology. 2013;38:2467–2474. doi: 10.1038/npp.2013.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Huuhka K, Viikki M, Tammentie T. One-year follow-up after discontinuing maintenance electroconvulsive therapy. J ECT. 2012;28:225–228. doi: 10.1097/YCT.0b013e3182548f93. [DOI] [PubMed] [Google Scholar]
  • 7.Martinez-Amoros E, Serra P, Goldberg X. Clinical outcome after discontinuation of maintenance electroconvulsive therapy. A retrospective follow-up study. Rev Psiquiatr Salud Ment. 2020;13:5–10. doi: 10.1016/j.rpsm.2019.07.001. [DOI] [PubMed] [Google Scholar]
  • 8.Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005;5:243–251. doi: 10.1038/nri1571. [DOI] [PubMed] [Google Scholar]
  • 9.Nielsen NR, Kristensen TS, Schnohr P. Perceived stress and cause-specific mortality among men and women: results from a prospective cohort study. Am J Epidemiol. 2008;168:481–491. doi: 10.1093/aje/kwn157. discussion 492-486. [DOI] [PubMed] [Google Scholar]
  • 10.Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med. 2020 doi: 10.1056/NEJMp2003539. [DOI] [PubMed] [Google Scholar]
  • 11.Lisanby SH, Sampson S, Husain MM. Toward individualized post-electroconvulsive therapy care: piloting the Symptom-Titrated, Algorithm-Based Longitudinal ECT (STABLE) intervention. J ECT. 2008;24:179–182. doi: 10.1097/YCT.0b013e318185fa6b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kellner CH, Husain MM, Knapp RG. A novel strategy for continuation ECT in geriatric depression: Phase 2 of the PRIDE study. Am J Psychiatry. 2016;173:1110–1118. doi: 10.1176/appi.ajp.2016.16010118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.World Health Organization P: Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected., 2020. https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125. Date last updated: 25 January, 2020. Date last accessed: 8 April, 2020.
  • 14.Swartz CM, Saheba NC. Comparison of atropine with glycopyrrolate for use in ECT. Convuls Ther. 1989;5:56–60. [PubMed] [Google Scholar]
  • 15.Rasmussen P, Andersson JE, Koch P. Glycopyrrolate prevents extreme bradycardia and cerebral deoxygenation during electroconvulsive therapy. J ECT. 2007;23:147–152. doi: 10.1097/YCT.0b013e318033ffd8. [DOI] [PubMed] [Google Scholar]
  • 16.Tran K, Cimon K, Severn M. 2011. Aerosol-Generating Procedures and Risk of Transmission of Acute Respiratory Infections: A Systematic Review.https://www.ncbi.nlm.nih.gov/books/NBK174437/CAfDaTiHNESAf edited by Available at. Ottawa (ON). Date last accessed: 8 April, 2020. [PMC free article] [PubMed] [Google Scholar]
  • 17.Simonds AK, Hanak A, Chatwin M. Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess. 2010;14:131–172. doi: 10.3310/hta14460-02. [DOI] [PubMed] [Google Scholar]
  • 18.Gomez-Arnau J, de Arriba-Arnau A, Correas-Lauffer J. Hyperventilation and electroconvulsive therapy: A literature review. Gen Hosp Psychiatry. 2018;50:54–62. doi: 10.1016/j.genhosppsych.2017.09.003. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Geriatric Psychiatry are provided here courtesy of Elsevier

RESOURCES